Psoriasis is a frequently occurring immune-mediated inflammatory skin disorder that causes red, itchy, scaly, patches of skin. It affects about 25 million people in North America and Europe, and at least 100 million people worldwide. Psoriasis is likely the most prevalent immune-mediated skin disease in adults.

There are five official types of psoriasis with the most common being plaque psoriasis making up 97% of all cases.

At Worldwide Clinical Trials, our experts understand that the commercial viability of therapeutics for chronic inflammatory disorders is influenced by a range of factors, including perceived value and therapeutic novelty — which is particularly relevant for illnesses with established treatments like psoriasis.